HIV drugs are top dollar
Posted by pozlife on April 21, 2007
The HIV drug market will be worth $10.6 billion worldwide by 2015, a report by industry market researchers Datamonitor said last week.
Datamonitor’s report says that despite continued pressure to cut drug prices in the developing world, selling antiretrovirals will remain a profitable business. The AIDS drug industry is already worth $7.1 billion, but will grow by at least 5% a year for the next 10 years. That’s only 1.1% of a total global drug market of $643 billion, but it’s not chicken feed.
The companies best poised to reap dividends are those that have invested in researching and developing drugs with new modes of action, the report says.
These include Merck and co for its integrase inhibitor raltegravir and possibly for its candidate HIV vaccine; Pfizer for its CCR5 inhibitor maraviroc and other drug classes in the pipeline; Johnson and Johnson, the giant that bought the Belgian biotech firm Tibotec and in the process the powerful protease inhibitor darunavir and the NNRTIs etravirine and rilpivirine; and Gilead, who have another integrase inhibitor in the works, continue to reap vast profits from tenofovir, and with BMS and Merck have developed the first one-pill, once-a-day HIV treatment, Atripla® (tenofovir/FTC/efavirenz).
The number of people living with HIV in North America and Western Europe went up from an estimated 1.9 million in 2004 to 2.1 million in 2006, and with cases increasing by 7,000 a year in the UK and 38,000 in the US, the increase is unlikely to slow down soon.
“Advances in antiretroviral therapy have turned HIV from a universally feared death sentence into a chronic disease with an average life expectancy similar to that of Type 2 diabetes,” Datamonitor analyst Mansi Shah said.
“Because of this, attitudes towards HIV have become relatively blasé amongst some groups.”